SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

08 Nov 2023 Evaluate
The sales figure stood at Rs. 36592.30 millions for the September 2023 quarter. The mentioned figure indicates a growth of about 29.35% as compared to Rs. 28289.60 millions during the year-ago period.The Net Profit of the company vaulted to 269.14% to Rs. 5486.10  millions from Rs. 1486.20 millions in the previous quarter.OP of the company witnessed a marginal growth to 8608.40 millions from 3290.30 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 36592.30 28289.60 29.35 71548.70 55614.50 28.65 112588.30 117716.70 -4.36
Other Income 256.00 153.70 66.56 533.40 218.50 144.12 912.60 1504.20 -39.33
PBIDT 8608.40 3290.30 161.63 15936.00 6242.10 155.30 11739.20 4261.30 175.48
Interest 153.20 183.80 -16.65 315.00 382.50 -17.65 984.40 734.70 33.99
PBDT 8455.20 3106.50 172.18 15621.00 5859.60 166.59 10754.80 3526.60 204.96
Depreciation 1494.80 1377.60 8.51 2895.30 2681.10 7.99 5483.40 5141.90 6.64
PBT 6960.40 1728.90 302.59 12725.70 3178.50 300.37 5271.40 -1615.30 -426.34
TAX 1474.30 242.70 507.46 2470.00 520.50 374.54 1019.30 271.70 275.16
Deferred Tax 177.70 -45.00 -494.89 166.20 -56.60 -393.64 60.40 -306.30 -119.72
PAT 5486.10 1486.20 269.14 10255.70 2658.00 285.84 4252.10 -1887.00 -325.34
Equity 910.50 909.40 0.12 910.50 909.40 0.12 910.00 909.00 0.11
PBIDTM(%) 23.53 11.63 102.27 22.27 11.22 98.44 10.43 3.62 188.03

Lupin Share Price

2396.20 -23.95 (-0.99%)
01-Jul-2026 15:50 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1869.50
Dr. Reddys Labs. 1337.40
Cipla 1457.50
Zydus Lifesciences 1108.85
Lupin 2396.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: